modelLactobacillus
Extends from Pharmacolibrary.Drugs.ATC.G.G01AX14.
Information
| name: | Lactobacillus | |
| ATC code: | G01AX14 | route: | vaginal |
| compartments: | 1 | |
| dosage: | 1 | mg |
| volume of distribution: | 1 | L |
| clearance: | 0 | L/h |
| other parameters in model implementation | ||
Lactobacillus is a genus of probiotic bacteria commonly used for the restoration and maintenance of the normal vaginal flora. It is used in the treatment and prevention of bacterial vaginosis and other vaginal infections. Products with Lactobacillus (ATC G01AX14) are typically not considered traditional pharmacological drugs, but rather live biotherapeutic agents. Not systemically absorbed; acts locally in the vagina. Approved for use in several countries for vaginal health.
Pharmacokinetics
No pharmacokinetic compartmental model parameters have been reported for vaginally administered live lactobacillus in healthy adult women. Lactobacillus acts locally in the vagina; systemic exposure and absorption are negligible.
References
Barbés, C, & Boris, S (1999). Potential role of lactobacilli as prophylactic agents against genital pathogens. AIDS patient care and STDs 13(12) 747–751. DOI:10.1089/apc.1999.13.747 PUBMED:https://pubmed.ncbi.nlm.nih.gov/10743538
Bala, V, et al., & Sharma, VL (2015). N-Alkyl/aryl-4-(3-substituted-3-phenylpropyl)piperazine-1-carbothioamide as dual-action vaginal microbicides with reverse transcriptase inhibition. European journal of medicinal chemistry 101 640–650. DOI:10.1016/j.ejmech.2015.07.021 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26209833
Sandrine, MNY, et al., & Désiré, DDP (2025). In silico molecular docking and predictive ADME properties, in vitro antioxidant scavenging capacities, and in vivo pharmacological activities to study the potential of Pterocarpus mildbraedii's Harms (Fabaceae) in preventing vaginal dysbiosis and risk factors for cardiovascular disease in an estropause rat model. Fitoterapia 183 106496–None. DOI:10.1016/j.fitote.2025.106496 PUBMED:https://pubmed.ncbi.nlm.nih.gov/40147737
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)